Management of patients with preformed reactive antibodies who are awaiting cardiac transplantation

American Journal of Critical Care

Volumn 14, Issue 1, 2005, Pages 46-51

  Ballew, Carole C ^a   Bergin, James D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTIBODY; ANTICOAGULANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; DRONABINOL; ERYTHROPOIETIN; GLUCONATE CALCIUM; HLA ANTIGEN; IMMUNOGLOBULIN; INFUSION FLUID; INOTROPIC AGENT; ONDANSETRON; POTASSIUM CHLORIDE; SUCROSE;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; APHERESIS; ARTICLE; B LYMPHOCYTE; BLEEDING DISORDER; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW SUPPRESSION; CELL COUNT; CIRCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DEVICE; ELECTROLYTE DISTURBANCE; FLUID THERAPY; GRAFT REJECTION; HEALTH CARE COST; HEALTH CENTER; HEALTH PROGRAM; HEART TRANSPLANTATION; HEART VENTRICLE; HEMODIALYSIS; HUMAN; HYPOCALCEMIA; INFECTION; INFECTION RISK; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INJURY; LUNG EMBOLISM; LYMPHOCYTE; NAUSEA; NEUTROPENIA; ORGAN DONOR; OSMOSIS; PROSPECTIVE STUDY; RECIPIENT; SERUM; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TIME; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 12144271224     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: 10.4037/ajcc2005.14.1.46     Document Type: Article

References (21)

1. Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64:1120-1125.
2. Moazami N, Itescu S, Williams MK, Argenziano M, Weinberg A, Oz M. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant. 1998;17:876-880.
3. Stringham JC, Bull DA, Fuller TC, et al. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant. 1998;18:160-165.
4. McKenna D, Eastlund T, Segall M, Noreen H, Park S. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant. 2002;21:1218-1224.
5. Loh E, Bergin JD, Couper GS, Mudge GH Jr. Role of panel-reactive antibody cross-reactivity in predicting survival after orthotopic heart transplantation. J Heart Lung Transplant. 1994;13:194-201.
6. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58-69.
7. Leech SH, Rubin S, Eisen HJ, et al. Cardiac transplantation across a positive lymphocyte cross-match in sensitized recipients. Clin Transplant. 2003;17(suppl 9):17-26.
8. Thompson JS, Thacker LR Jr, Takemoto S. The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: an analysis from the United Network of Organ Sharing Scientific Registry. Transplantation. 2000;69:2178-2186.
9. Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation. 1998;98:786-793.
10. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation. 1999;100(19 suppl):II229-II235.
11. Triulzi D. Transfusion support in solid-organ transplantation. Transfusion Med Update. April 2001:1-4.
12. Mehra M, Uber P, Uber W, Scott R, Park M. Allosensitization in heart transplantation: implications and management strategies. Curr Opin Cardiol. 2003;18:153-158.
13. Dowling RD, Jones MS, Carroll MS, Gray LA. Use of intravenous immunoglobulin in sensitized LVAD recipients. Transplant Proc. 1998;30:1110-1111.
14. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18:701-706.
15. Brodsky RA, Fuller AK, Ratner LE, Leffell MS, Jones RJ. Elimination of alloantibodies by immunoablative high-dose cyclophosphamide. Transplantation. 2001;71:482-484.
16. Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J Clin Apheresis. 1994;9:1-5.
17. Cayco A, Preazella M, Hayslett J. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. Am Soc Nephrol. 1997;3:1788-1794.
18. Stahl M, Schifferli J. The renal risks of high-dose intravenous immunoglobulin treatment. Nephrol Dial Transplant. 1998;13:2182-2185.
19. Epstein JS, Gaines A, Kapit R, Pierce R, Varricchio F. Important drug: immune globulin intravenous. FDA Med Bull. Summer 1999. Available at: http://www.fda.gov/medbull/summer99/Globulin.html. Accessed September 13, 2004.
20. Reimann PM, Mason PM. Plasmapheresis: techniques and complications. Intensive Care Med. 1990;16:3-10.
21. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994;23:817-827.